Overview

* Compass Pathways ( CMPS ) Q3 net loss driven by non-cash warrant liabilities adjustment

* Company accelerates COMP360 commercialization plans by 9-12 months after FDA discussions

* Operating income for Q3 beats analyst expectations

Outlook

* Company accelerating commercial launch of COMP360 by 9-12 months

* COMP360 9-week data from COMP006 expected in Q1 2026

* COMP360 26-week data from COMP006 expected in early Q3 2026

Result Drivers

* R&D - Expenses were $27.3 million for the three months ended September 30, 2025, compared with $32.9 million during the same period in 2024. T

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$1.44

Q3 Net -$137.71

Income mln

Q3 Beat -$40.53 -$42.70

Operatin mln mln (8

g Income Analysts

)

Q3 $40.53

Operatin mln

g

Expenses

Q3 -$137.94

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Compass Pathways PLC ( CMPS ) is $14.00, about 57.5% above its November 3 closing price of $5.95

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)